Serensil en es it fr

Serensil Brand names, Serensil Analogs

Serensil Brand Names Mixture

  • No information avaliable

Serensil Chemical_Formula

C2H8O7P2

Serensil RX_link

http://www.rxlist.com/cgi/generic2/didronel.htm

Serensil fda sheet

Serensil FDA

Serensil msds (material safety sheet)

Serensil MSDS

Serensil Synthesis Reference

No information avaliable

Serensil Molecular Weight

206.028 g/mol

Serensil Melting Point

No information avaliable

Serensil H2O Solubility

No information avaliable

Serensil State

Solid

Serensil LogP

-2.734

Serensil Dosage Forms

Solution for injection (50mg/mL); Tablet (200, 400 mg)

Serensil Indication

For the treatment of symptomatic Paget's disease of bone and in the prevention and treatment of heterotopic ossification following total hip replacement or due to spinal cord injury.

Serensil Pharmacology

Etidronate is a first generation (non-nitrogenous) bisphosphonate in the same family as clodronate and tiludronate. Etidronate affects calcium metabolism and inhibits bone resorption and soft tissue calcification. Of the etidronate that is resorbed (from oral preparation) or infused (for intravenous drugs), about 50% is excreted unchanged by the kidney. The remainder has a very high affinity for bone tissue, and is rapidly absorbed onto the bone surface. Etidronate has been shown to prevent or delay skeletal-related events and decrease bone pain as well as normalize calcium levels in the presence of hypercalcemia.

Serensil Absorption

The amount of drug absorbed after an oral dose is approximately 3%.

Serensil side effects and Toxicity

Clinical experience with acute etidronate overdosage is extremely limited. Decreases in serum calcium following substantial overdosage may be expected in some patients. Signs and symptoms of hypocalcemia also may occur in some of these patients. Some patients may develop vomiting. In one event, an 18-year-old female who ingested an estimated single dose of 4800 to 6000 mg (67 to 100 mg/kg) of etidronate was reported to be mildly hypocalcemic (7 .5 2 mg/ dl) and experienced paresthesia of the fingers.

Serensil Patient Information

Serensil Organisms Affected

Humans and other mammals